Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms
TET2 and DNMT3A mutations are frequently identified in T-cell lymphomas of T follicular helper cell origin (TCL-TFH), clonal hematopoiesis (CH), and myeloid neoplasms (MNs). The relationships among these 3 entities, however, are not well understood. We performed comprehensive genomic studies on paired bone marrow and tissue samples as well as on flow cytometry–sorted bone marrow and peripheral blood subpopulations from a cohort of 22 patients with TCL-TFH to identify shared CH-type mutations in various hematopoietic cell compartments. Identical mutations were detected in the neoplastic T-cell and myeloid compartments of 15 out of 22 patients (68%), including TET2 (14/15) and DNMT3A (10/15). Four patients developed MNs, all of which shared CH-type mutations with their TCL-TFH; additional unique genetic alterations were also detected in each patient’s TCL-TFH and MN. These data demonstrate that CH is prevalent in patients with TCL-TFH and that divergent evolution of a CH clone may give rise to both TCL-TFH and MNs.
Top-30
Journals
|
1
2
3
4
5
|
|
|
Frontiers in Oncology
5 publications, 5.56%
|
|
|
Leukemia
5 publications, 5.56%
|
|
|
Blood
5 publications, 5.56%
|
|
|
Modern Pathology
4 publications, 4.44%
|
|
|
Virchows Archiv
4 publications, 4.44%
|
|
|
American Journal of Clinical Pathology
4 publications, 4.44%
|
|
|
Cancers
3 publications, 3.33%
|
|
|
British Journal of Haematology
3 publications, 3.33%
|
|
|
Annals of Hematology
3 publications, 3.33%
|
|
|
New England Journal of Medicine
3 publications, 3.33%
|
|
|
International Journal of Molecular Sciences
2 publications, 2.22%
|
|
|
Leukemia and Lymphoma
2 publications, 2.22%
|
|
|
Clinical Lymphoma, Myeloma and Leukemia
2 publications, 2.22%
|
|
|
International Journal of Hematology
2 publications, 2.22%
|
|
|
Die Pathologie
2 publications, 2.22%
|
|
|
Histopathology
2 publications, 2.22%
|
|
|
American Journal of Hematology
2 publications, 2.22%
|
|
|
Blood advances
2 publications, 2.22%
|
|
|
Human Pathology
2 publications, 2.22%
|
|
|
Current Opinion in Oncology
1 publication, 1.11%
|
|
|
Signal Transduction and Targeted Therapy
1 publication, 1.11%
|
|
|
Current Oncology
1 publication, 1.11%
|
|
|
Hemato
1 publication, 1.11%
|
|
|
Current Oncology Reports
1 publication, 1.11%
|
|
|
Journal of Experimental and Clinical Cancer Research
1 publication, 1.11%
|
|
|
Oncogenesis
1 publication, 1.11%
|
|
|
Leukemia Research
1 publication, 1.11%
|
|
|
Clinics in Laboratory Medicine
1 publication, 1.11%
|
|
|
Blood Reviews
1 publication, 1.11%
|
|
|
1
2
3
4
5
|
Publishers
|
5
10
15
20
25
|
|
|
Springer Nature
23 publications, 25.56%
|
|
|
Elsevier
17 publications, 18.89%
|
|
|
Wiley
12 publications, 13.33%
|
|
|
MDPI
7 publications, 7.78%
|
|
|
American Society of Hematology
7 publications, 7.78%
|
|
|
Frontiers Media S.A.
5 publications, 5.56%
|
|
|
Oxford University Press
4 publications, 4.44%
|
|
|
Cold Spring Harbor Laboratory
3 publications, 3.33%
|
|
|
Massachusetts Medical Society
3 publications, 3.33%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
2 publications, 2.22%
|
|
|
Taylor & Francis
2 publications, 2.22%
|
|
|
Ferrata Storti Foundation
1 publication, 1.11%
|
|
|
American Association for Cancer Research (AACR)
1 publication, 1.11%
|
|
|
eLife Sciences Publications
1 publication, 1.11%
|
|
|
American Society of Clinical Oncology (ASCO)
1 publication, 1.11%
|
|
|
5
10
15
20
25
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.